{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG002","value":"14.3"},{"groupId":"OG003","value":"0.0"},{"groupId":"OG004","value":"0.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"4"}],"units":"Participants"}],"description":"Objective response rate for patients with Epidermal Growth Factor Receptor (EGFR) T790M mutations. Objective response was defined as Complete Response (CR): Disappearance of all target lesion or Partial Response and (PR): \\>=30% decrease in the sum of the longest diameter of target lesions, according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1.\n\nThis endpoint was originally planned to be analysed in part B of the study, however as no participants were treated in part B the analysis was performed on the part A participants.","groups":[{"description":"Patients received oral administration of afatinib 90mg film-coated tablet once daily for three days, repeated every 14 days, during each 28-day cycle.","id":"OG000","title":"Afatinib 90mg"},{"description":"Patients received oral administration of afatinib 120mg film-coated tablet once daily for three days, repeated every 14 days, during each 28-day cycle.","id":"OG001","title":"Afatinib 120mg"},{"description":"Patients received oral administration of afatinib 150mg film-coated tablet once daily for three days, repeated every 14 days, during each 28-day cycle.","id":"OG002","title":"Afatinib 150mg"},{"description":"Patients received oral administration of afatinib 160mg film-coated tablet once daily for three days, repeated every 14 days, during each 28-day cycle.","id":"OG003","title":"Afatinib 160mg"},{"description":"Patients received oral administration of afatinib 200mg film-coated tablet once daily for three days, repeated every 14 days, during each 28-day cycle.","id":"OG004","title":"Afatinib 200mg"}],"paramType":"NUMBER","populationDescription":"Treated set including participants with EGFR T790M positive mutations","reportingStatus":"POSTED","timeFrame":"From first drug administration until last drug administration, up to 420 days","title":"Objective Response Rate for Patients With EGFR T790M Mutations","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}